KURA Latest Headlines

Kura Oncology Earnings Call Signals Early Launch Strength

at www.tipranks.com (Wed, 20-May 1:29 AM)

Kura Oncology (KURA) Receives a Buy from LifeSci Capital

at www.tipranks.com (Sat, 16-May 10:35 AM)

Kura Oncology’s Darlifarnib Combo Achieves 44% Response Rate in Difficult-to-Treat RCC—Signals Potential to Overcome Drug Resistance

Market Chameleon (Fri, 17-Apr 11:46 AM)

Darlifarnib Plus Cabozantinib Shows Strong Response Rates in Heavily Pretreated Renal Cell Carcinoma—44% ORR and 94% DCR Stand Out

Market Chameleon (Fri, 17-Apr 7:28 AM)

Kura Oncology’s Early KOMZIFTI Revenue Momentum and Strong Balance Sheet Stand Out Amid 2025 Results

Market Chameleon (Thu, 5-Mar 8:45 AM)